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Effects of intensity, attention 
and medication on auditory‑evoked 
potentials in patients 
with fibromyalgia
N. Samartin‑Veiga1*, A. J. González‑Villar1,2, Y. Triñanes1, C. Gómez‑Perretta3,4 & 
M. T. Carrillo‑de‑la‑Peña1
Fibromyalgia (FM) has been associated to an increased processing of somatosensory stimuli, but its 
generalization to other sensory modalities is under discussion. To clarify this, we studied auditory 
event‑related potentials (AEPs) to stimuli of different intensity in patients with FM and healthy 
controls (HCs), considering the effects of attention mechanisms and medication. We performed 
two experiments: In study 1 (n = 50 FM, 60 HCs), the stimuli were presented randomly within the 
sequence; in study 2 (n = 28 FM, 30 HCs), they were presented in blocks of the same intensity. We 
analyzed intensity and group effects on N1‑P2 amplitude and, only for the FM group, the effect of 
medication and the correlation between AEPs and clinical variables. Contrary to the expectation, 
the patients showed a trend of reduced AEPs to the loudest tones (study 1) or no significant 
differences with the HCs (study 2). Medication with central effects significantly reduced AEPs, 
while no significant relationships between the N1‑P2 amplitude/intensity function and patients’ 
symptoms were observed. The findings do not provide evidence of augmented auditory processing 
in FM. Nevertheless, given the observed effect of medication, the role of sensory amplification as an 
underlying pathophysiological mechanism in fibromyalgia cannot be discarded.
Fibromyalgia (FM) is a complex chronic syndrome that affects around 5% of the population, producing a remark-
able burden on their quality of  life1. FM is mainly characterized by widespread pain, constant tiredness and 
fatigue, cognitive dysfunction, and non-restorative sleep. Despite extensive research, the etiology and patho-
genesis of FM remain unclear. Several studies postulate that the patients with FM present dysfunction of central 
nervous system mechanisms, affecting both nociceptive and non-nociceptive  processing2–5, and including altera-
tion in the descending pain modulation  mechanisms3,6.
Based on those evidences, it has been proposed that central amplification of painful and non-painful sensory 
inputs may be at the basis of this syndrome, as well as of other chronic pain  diseases7. For FM, this hypothesis 
has received consistent support in the somatosensory modality: patients show increased pain scores and less 
tolerance to noxious  stimuli8–12 as well as alterations in electroencephalography (EEG) activity and deficits in 
habituation while processing somatosensory stimuli (painful and non-painful)13–18. However, although patients 
with FM report increased sensitivity to olfactory, auditory and, visual  stimuli19,20, the evidence supporting the 
generalization of this pattern of central amplification to modalities other than somatosensory is not conclusive.
In the auditory modality, several studies reported augmented subjective perception of tones intensity and 
lower tolerance to noise by FM  patients19,21. Also, using a validated paradigm,—the loudness dependence of 
the Auditory Evoked Potentials (AEPs)—, Carrillo-de-la-Peña22 found greater amplitude of the brain electrical 
response evoked by intense auditory stimuli in FM patients. In contrast, other authors did not find differences 
in auditory cortical responses between the FM and the control  groups15,23,24. These inconsistencies in the litera-
ture may be due to differences in paradigms and stimulation parameters. For instance, some studies employed a 
paired click paradigm to analyze preattentional  components15,24, while others analyze later brain  responses22,23. 
In addition, some authors argue that the inconsistent results may be due to the stimuli intensity, sometimes not 
powerful enough to be unpleasant and to elicit changes in information  processing25. However, this suggestion 
OPEN
1Departamento de Psicoloxía Clínica e Psicobioloxía, Facultade de Psicoloxía, Universidade de Santiago de 
Compostela, Santiago de Compostela, Spain. 2Psychological Neuroscience Lab, Psychology Research Centre, 
School of Psychology, University of Minho, Braga, Portugal. 3Research Foundation of La Fe Hospital, Valencia, 
Spain. 4C. Gómez-Perretta is deceased. *email: noelia.samartin.veiga@usc.es
2
Vol:.(1234567890)
Scientific Reports |        (2020) 10:21904  | https://doi.org/10.1038/s41598-020-78377-0
www.nature.com/scientificreports/
goes against the hypothesis of a generalized hypervigilance in FM, which should be present to both nociceptive 
and harmless  stimuli26,27.
Pain perception and attention proccesses share neural  substrates28,29. Different modes of attention to painful 
stimuli (bottom-up vs. top-down) differentially modulate the evoked brain  response30,31. Since the presentation 
of auditory stimuli in blocks or in a random sequence may engage different attentional  procesess32,33, it would 
be interesting to analyze the effect of attention on AEPs recorded while processing tones of increasing intensity 
in a sample of patients with FM, as compared to healthy controls. Also, as previous studies suggest that the effect 
of medication may explain, at least partially, the inconsistencies in the  literature24,34, the control of this variable 
is of paramount importance.
Therefore, the aim of the present paper was to analyze the brain electrical activity to auditory stimuli varying 
in intensity, and whether that response depend on the attentional mechanism involved, in a sample of patients 
with FM and healthy controls. To this end, we recorded AEPs to two tones sequences: random presentation 
(study 1), where the subject could not anticipate the appearance of the louder stimuli (involving bottom-up 
mechanisms); and presentation in blocks of equal intensity (study 2), where the subject could anticipate the 
intensity of the following stimuli (involving top-dow mechanims). According to the increased sensory processing 
hypothesized for FM, we expected to find larger AEPs to the more intense tones in the patients, specially when 
they are predictable, as in the blocks presentation.
To control for the effect of medication, we compared patients using or not mediation with central nervous 
system (CNS) effects (antidepressive, anxiolytic, anticonvulsivant, etc.). Furthermore, since the intensity depend-
ence of the AEPs has been proposed as an indicator of the serotonin  function35–38, linked to pain  inhibition39,40, 
and mood  regulation41, we expected to find a positive correlation between the intensity/amplitude function of 
the AEPs, and FM symptoms’ severity.
Methods
Participants. For study 1, we recruited 50 patients with FM (mean age: 47.30; SD: 8.00) and 60 healthy con-
trols (HC) (mean age: 45.06; SD: 10.34) and for study 2, 28 patients with FM (mean age: 50.31; SD: 9.20) and 30 
HC (mean age: 48.44; SD: 11.18). All the participants were female and both groups were matched for age in each 
study. The patients with FM had a previous diagnosis confirmed by their primary care physician or rheumatolo-
gist and had no other disease that could explain chronic pain nor mental disorders (except mild/moderate levels 
of depression, or anxiety). The same exclusion criteria were applied to the participants of the control group, who 
also should not have chronic pain problems. Additional exclusion criteria for both groups comprised a history 
of substance abuse or brain damage.
The diagnosis of participants was confirmed using the 1990 ACR  criteria42 and/or the 2010 ACR  criteria43,44. 
Moreover, in both studies, the participants were evaluated though a comprehensive clinical interview and several 
self-reported questionnaires (see “Clinical assessment”). Also, only in study 1, we assessed the 18 tender points 
by pressure algometry. Written informed consent was obtained from all the participants and they were coded 
by numbers. The studies were approved by the Ethics Committee of the University of Santiago de Compostela 
and were executed in accordance with the Code of Ethics of the Declaration of the World Medical Association 
in Helsinki, 2013.
Clinical assessment. Study 1. Participants completed several self-reported questionnaires for the assess-
ment of FM symptoms (all in their validated Spanish versions).
Visual-analogue scales (VAS). They were created ad-hoc to evaluate the clinical status of participants. The 
scales consist of a set of horizontal 10 cm-long lines where participants had to indicate their status in the follow-
ing variables: pain, health status, mood status, and non-restorative sleep. All the scales were presented so that the 
left end indicated the best condition, and the right the worst.
Fibromyalgia impact questionnaire (FIQ)45,46. The FIQ is a self-reported questionnaire of 10 items to evaluate 
the health status of patients with FM. It includes indices of functionality as well as the core symptoms of fibro-
myalgia, with a maximum score of 100 (higher scores are associated to more severe symptoms).
SF-36 health  survey47,48. The SF-36 is a questionnaire that assesses quality of life. It is made up of 36 items that 
cover 8 dimensions (physical functioning, role physical, bodily pain, general health, vitality, social functioning, 
role emotional, and mental health) and provide a profile of health status and functionality. For each dimension, 
the items are coded, added and transformed into a range of 0–100 (from the worst health status to the best health 
status). We computed a mean of the 8 dimensions to obtain a general index of quality of life (SF-36 general).
Beck depression inventory (BDI)49,50. The BDI evaluates depressive symptomatology using 21 items scored 
from 0 to 3 (the higher the score, the higher the severity of depressive symptoms).
The pittsburgh sleep quality index (PSQI)51,52. The Spanish validation of the PSQI was used to assess the quality 
and dysfunction of sleep in the last month. It is composed of 7 subscales (from 0 -no difficulty- to 3 -maximum 
difficulty-) that describe different aspects of sleep problems. The overall score has an interval of 0–21, where the 
highest scores indicate a worse quality of sleep.
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Algometry. We measured the pain threshold and tolerance at the 18 tender points using a pressure algom-
eter (Wagner Force One, Model FDI; Wagner Instruments, Greenwich, CT, USA). Pressure pain threshold was 
defined as the minimum force applied that induces pain, and pressure pain tolerance as the maximum pain-
pressure value that was bearable. These measures were quantified at each of the 18 specific tender point sites 
according to the ACR 1990 criteria for FM. A tender point was considered positive when the patient felt pain at 
pressures equal or less than 4 kg/cm2. For each participant we calculated the total count of positive tender points 
and the mean pain-pressure threshold and tolerance at the 18 points.
Study 2. As in study 1, the participants completed several self-reported questionnaires (including VAS, BDI, 
and PSQI). To assess the diagnostic criteria proposed by  Wolfe43, we used the Spanish version of the Fibromyal-
gia Survey Questionnaire (FSQ)44 originally published by  Wolfe53. It includes the Symptom Severity Scale (SSS), 
which considers 3 key symptoms (fatigue, cognitive problems (attention, concentration, or memory), and non-
restorative sleep) and others such as abdominal pain, depression, and headache; and the Widespread Pain Index 
(WPI) that indicates the number of body areas with pain reported by the patient.
Procedure and task. Participants were asked to not smoke, consume coffee, alcohol, or other drugs not 
medically prescribed before evaluation. At first, participants completed the clinical interview and self-reported 
questionnaires. In study 1, the 18 tender points (ACR, 1990) were evaluated in patients and control participants 
using a pressure algometer. In both experiments the participants were seated in a comfortable chair in a room 
isolated from external sounds and with dim light. After that, participants were fitted with an electrode cap to 
register their EEG.
In study 1, before the recording, the audiological status of both ears was verified by evaluation of the audi-
tory threshold (Békésy’s method). Four patients with FM and one healthy control were discarded due to their 
high thresholds in the audiometry. Also, one patient with FM was eliminated due to technical problems during 
the EEG recording. AEPS were obtained using a pseudo-randomized series of 288 auditory stimuli, 72 of each 
intensity (S1 = 70, S2 = 80, S3 = 90; and S4 = 105 dB SPL). The stimuli had a frequency of 1000 Hz and a duration 
of 50 ms, with a random interstimuli interval of 1500 ± 100 ms. Each intensity was equally preceded by each one 
of the other 3 intensities.
In study 2, two patients with FM were discarded due to hearing impairment and complains of annoyance by 
the loudest tones during the recording, respectively. The task consisted of 180 trials, 60 of each intensity (S1 = 70, 
S2 = 90; and S3 = 105 dB SPL), presented in blocks of equal intensity. The stimuli had a frequency of 1000 Hz 
and a duration of 50 ms, with a random interstimuli interval of 1400 ± 100 ms. There were two forms of stimuli 
presentation (increasing or decreasing intensity) which were counterbalanced across participants.
Recording and processing of AEPs. Brain electrical activity was recorded during the presentation of the 
sounds. In the study 1, the EEG was recorded using a 32-electrocap (Electro-cap International, Inc., Eaton, OH, 
USA) and a Synamps amplifier (Neuroscan Labs, Charlotte, NC, USA) for EEG collection, amplification and 
online filtering. In the study 2, an ActiChamp system with 32 electrodes cap (Brain Products inc.) was used. The 
electrodes were placed according to the 10-20 International System, with the reference electrode in the tip of the 
nose. The ground electrode was placed in the Fpz position. Additional electrodes were placed 1 cm above and 
below the eyes and other two were placed on the outer edge of each eye to correct vertical and horizontal eye 
movements. The EEG was digitized at 500 Hz, 10,000× amplified, and filtered with a 0.1–100 Hz band pass filter 
and a 50 Hz notch filter. Impedances were kept below 10 KΩ.
EEG data were analyzed using the EEGlab 13.3  toolbox54. The EEG was re-referenced to an average reference. 
A spherical-spline interpolation was used to reconstruct bad channels. EEG noisy segments, produced by eye 
movements or other contaminants, were rejected by visual inspection. The data were digitally filtered using a 
0.5 Hz high pass filter and a 30 Hz low pass filter. Epochs were extracted from 0.4 s pre-stimulus to 1.2 s post-
stimulus. An extended Independent Component Analysis algorithm (ICA) was applied to the electrophysiological 
 data55, and components related to ocular or muscular activity were removed after visual inspection.
The EEG epochs used for the analysis of AEPs were corrected using a baseline from − 0.2 to 0 s. We measured 
N1 and P2 peak amplitudes at each stimuli intensity in electrodes Fz and Cz, given that these are the locations 
where such components usually show their greatest  amplitudes32. In study 1, the N1 component was identified 
as the most negative peak within the range 50–160 ms in Fz, and within the range 90–160 ms in Cz; and P2 as 
the most positive peak within the range 150–300 ms in Fz and Cz. In study 2, N1 was identified as the most 
negative peak within the range 80–150 ms in Fz and Cz; and P2 as the most positive peak within the range 
150–300 ms in Fz, and within the range 160–300 ms in Cz. The amplitude of N1-P2 was calculated as the peak-
to-peak difference.
Data analyses. Student t-tests were performed to evaluate possible differences between groups in demo-
graphic and clinical variables. Also we calculated the percentages of patients using each medication pattern 
(classified by: analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), anxiolytics, opioids, migraine medi-
cation, antidepressants, sedatives, and antiepileptic drugs). Repeated measures ANOVAs with Electrode (Fz 
vs. Cz) and Intensity (70, 80, 90, 105 dB; or 70, 90, 105 dB, for study 1 and 2, respectively) as intra-subject fac-
tors and Group (FM vs. HCs) as a between-subject factor were conducted for N1-P2 amplitude in each study. 
We adjusted the degrees of freedom by the Greenhouse–Geisser correction to determine the significance levels 
when the sphericity assumption was violated. For patients with FM, we additionally performed a mixed model 
ANOVA with Electrode and Intensity as intra-subject factors and Medication Group (with vs. without central 
medication) as a between-subject factor on N1-P2 amplitude. Effect size analyses were undertaken to assess the 
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magnitude of differences between the groups (Cohen’s d). Finally, Pearson’s correlation analyses were performed 
to evaluate the relation between psychophysiological and clinical variables; for this purpose, we first calculated 
the amplitude/intensity slope of the N1-P2 by linear regression for each subject, as a measure of the intensity 
dependence of the AEPs. Then, we calculated the correlations with the clinical indices, for the total FM group, 
and separately for each group of medication. All these statistical analyses were performed with SPSS (v. 20; 
http://www.ibm.com). Significance level was p value < 0.05.
Results
Study 1. Demographic and clinical variables. As may be seen in Table 1, t-tests confirmed that both groups 
were comparable in age. Patients showed significantly more affectation in all the FM symptoms, as well as lower 
pressure pain threshold and tolerance values, with large effect sizes (Cohen’s d > 0.80)  [56; pp. 280–287]. Although 
all the patients were previously diagnosed according to the ACR  recommendations42, we found that 5 of them 
did not fulfill the criterion of having more than 11 tender points with values lower than 4 kg/cm2. Due to the 
criticisms around this  criterion57, we decided to retain those participants for the analyses. The medication pat-
tern of the patients was the following: 24% of them used NSAIDs, 28% anxiolytics, 30% antidepressants and 6% 
antiepileptic (see Supplementary material; Supplementary Table S1).
AEPs to tones. Figure 1 (random presentation) shows larger N1-P2 amplitudes at Cz than Fz, and linear ampli-
tude increases as intensity increased, as well as differences between both groups only for the most intense tones. 
Also, it can be seen that the topographical distribution of N1 was fronto-central, while the distribution of P2 was 
centro-parietal in both groups.
A repeated measures ANOVA on N1-P2 amplitude showed a significant effect of Electrode  [F(1,102)=143.11; 
p < 0.001; Cohen’s d = 2.35], Intensity  [F(3,306) = 141.82; p < 0.001; Cohen’s d = 2.35], and Electrode × Intensity 
 [F(3,306) = 78.33; p < 0.001; Cohen’s d = 1.73]. The amplitudes increased as the stimuli intensity increased, being 
larger at Cz than Fz, specially for the highest intensities. Post-hoc comparisons revealed significant differences 
between each pair of intensity level (S1 vs. S2; S1 vs. S3; S1 vs. S4; S2 vs. S3; S2 vs. S4; S3 vs. S4), in both electrodes. 
Also we found a significant Intensity × Group interaction  [F(3,306) = 2.84; p = 0.038; Cohen’s d = 0.28], with a small 
effect size (d > 0.20). As may be seen in Table 2, the patients showed slightly larger amplitudes to the intensities 
S1, S2, and S3, but smaller to the S4, as compared to the healthy controls. However, no significant differences 
were observed in post-hoc comparisons.
We divided the patients sample according to their medication pattern (24 patients using CNS medication; 21 
patients non using CNS medication). The ANOVA performed to assess the effect of medication in the FM group 
revealed significant effects for Electrode  [F(1,43) = 84.71; p < 0.001; Cohen’s d = 2.78]; Intensity  [F(3,129) = 49.79; 
p < 0.001; Cohen’s d = 2.12], and Intensity × Electrode  [F(3,129) = 31.55; p < 0.001; Cohen’s d = 1.70]. Also, we found 
a main effect of Group of Medication  [F(1,43) = 5.10; p = 0.029; Cohen’s d = 0.66], with a medium effect size (d > 0.5). 
Post-hoc comparisons revealed that patients using medication with central effects showed smaller N1-P2 ampli-
tudes (mean = 10.98 µV) than patients without medication affecting the CNS (including non-medicated patients 
or patients using anti-inflamatory or peripheral analgesics; mean N1-P2 amplitude = 13.96 µV), irrespective of 
the intensity and electrode (see Fig. 2).
Finally, we calculated the intensity/amplitude slope of N1-P2 at Cz (because it was the electrode showing 
the largest amplitudes) for the patients and correlated it with the clinical variables. No significant correlation 
was observed with any of the FM symptoms (assessed by VAS, FIQ, SF-36, BDI, PSQI, and pain threshold and 
tolerance values), irrespective of the patients’ medication pattern.
Table 1.  Demographic and clinical variables for patients with fibromyalgia (FM) and healthy controls (HC). 
Results of the t-tests comparisons and effect sizes (Cohen’s d). VAS: Visual Analogue Scale; FIQ: Fibromyalgia 










Mean (SD) t P Cohen’s d
Age 50 47.30 (8.00) 60 45.06 (10.34) 1.27 n.s –
Years of education 49 16.94 (4.32) 56 19.11 (4.56) − 2.49  <  0.05 0.20
VAS pain 49 6.82 (1.99) 57 1.83 (2.14) 12.35  < 0.001 2.41
VAS health status 50 6.82 (2.20) 57 1.87 (2.50) 10.79  <  0.001 2.10
VAS mood status 50 4.45 (2.81) 57 1.69 (2.01) 5.77  <  0.001 1.13
VAS non-restorative sleep 50 7.24 (2.72) 57 2.73 (2.92) 8.24  <  0.001 1.60
FIQ total 50 64.51 (15.67) – – – – –
SF36 general 49 41.16 (14.16) 57 79.80 (11.70) − 15.38  <  0.001 2.97
BDI 50 19.22 (9.43) 58 5.57 (5.93) 8.84  <  0.001 1.73
PSQI total 49 12.63 (4.44) 56 5.21 (3.58) 9.47  <   0.001 1.84
Tolerance (algometry) 49 3.21 (1.04) 58 6.11 (1.02) − 14.49  <  0.001 2.82
Threshold (algometry) 49 2.42 (0.82) 58 5.55 (0.99) − 17.61  <  0.001 3.44
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Study 2. Demographic and clinical variables. As may be seen in Table 3, both groups were comparable in 
age and level of education. Concerning the clinical variables, patients with FM were overall more affected than 
controls. Effect size analyses for the clinical variables (VAS, SSS, WPI, BDI and, PSQI) showed a large effect (Co-
hen’s d > 0.80). The percentage of patients using each type of medication was the following: 33.3% used analge-
sics, 33.3% NSAIDs, 51.9% anxiolytics, 22.2% opioids, 3.7% migraine medication, 48.1% antidepressants, 14.8% 
sedatives, and 22.2% antiepileptic drugs (see Supplementary material; Supplementary Table S2).
Figure 1.  Right. Electrical brain activity in response to auditory stimulation in patients with fibromyalgia (FM) 
and healthy controls (HC). The waveforms represent the auditory evoked potentials (AEPs) at electrodes Fz 
(up) and Cz (bottom) elicited by the tones of 70 dB (S1; blue line), 80 dB (S2; black line), 90 dB (S3; red line) 
and, 105 dB (S4; green line). Left. Spatial distribution of the electrical activity elicited by stimuli of different 
intensities. The upper part shows the topographic representation of N1 (measured as the mean value from 50 
to 160 ms after the presentation of the stimuli), and the lower part shows the topography of P2 (measured from 
150 to 300 ms).
Table 2.  Left: N1-P2 peak-to-peak amplitudes (in µV) measured at the Fz and Cz electrodes to the different 
intensities (S1, S2, S3 and S4) (standard deviations in parentheses), for patients with Fibromyalgia (FM) and 
healthy controls (HC). Right: Repeated measures ANOVA analysis significant results and effect sizes (Cohen’s 
d).
Stimuli
FM (n = 45) HC (n = 59)
ANOVA resultsN1-P2 amplitude N1-P2 amplitude
Fz Cz Fz Cz F (p) Cohen’s d
S1 (70 dB) 9.09 (3,96) 10.46 (4.46) 8.53 (3.17) 9.47 (3.24) Electrode effect 143.11 (< .001) 2.35
S2 (80 dB) 10.78 (4.74) 12.74 (4.92) 9.60 (3.71) 11.05 (3.96) Intensity effect 141.82 (< .001) 2.35
S3 (90 dB) 10.78 (4.74) 13.87 (4.93) 9.60 (3.71) 12.79 (4.52) Elecgrode × intensity effect 78.338 (< .001) 1.73
S4 (105 dB) 13.42 (5.93) 17.81 (6.98) 13.91 (5.83) 17.97 (7.23) Intensity × group effect 2.84 (< .05) 0.28
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AEPs to tones. As may be seen in Fig. 3, in this study (applying a block presentation) we also observed larger 
N1-P2 amplitudes over Cz than Fz for all the intensities, and similar topographies for N1 and P2 than in study 1. 
At odds with the previous study, the larger N1-P2 amplitudes were not associated to the loudest tones.
A repeated measures ANOVA on N1-P2 peak-to-peak amplitude showed a significant effect of Electrode 
 [F(1,54) = 34.72; p =  < 0.001; Cohen’s d = 1.59], Intensity  [F(2,108) = 20.55; p =  < 0.001; Cohen’s d = 1.24], and Elec-
trode x Intensity  [F(2,108) = 18.31; p =  < 0.001; Cohen’s d = 1.15]. Post-hoc comparisons revealed that the N1-P2 
amplitudes to the highest intensity (S3) were not significantly larger to those for the lowest intensities (S1 or S2). 
As may be seen in Table 4, the HC showed slightly larger amplitudes in the intensities towards all the stimuli 
regardless of the electrode; however, the analysis did not show significant effects of Group.
We divided the sample of patients according to their consumption of medication (17 patients using CNS 
medication and 8 patients non using CNS medication). The ANOVA showed significant effects for Intensity 
 [F(2,46) = 7.74; p < 0.01; Cohen’s d = 1.15], Electrode  [F(1,23) = 10.34; p < 0.01; Cohen’s d = 1.34], and Intensity × 
Figure 2.  Electrical brain activity in response to auditory stimulation in patients with fibromyalgia without 
CNS medication (UNMED) or with CNS medication (MED). The waveforms represent the auditory evoked 
potentials (AEPs) at electrodes Fz (up) and Cz (bottom) elicited by the tones of 70 dB (S1; blue line), 80 dB (S2; 
black line), 90 dB (S3; red line) and, 105 dB (S4; green line).
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Electrode  [F(2,46) = 4.05; p = 0.024; Cohen’s d = 0.84]. Although the patients with CNS medication (n = 17) showed 
smaller N1-P2 amplitudes that patients without it (n = 8; 5.90 µV vs. 7.43 µV), the effect of Group of medication 
did not reach the significance level  [F(1,23) = 3.07; p = 0.093] (see Fig. 4).
Finally, no significant correlation was found between FM symptoms (assessed by VAS, SSS, WPI, BDI, and 
PSQI) and the amplitude/intensity slope of the N1-P2 complex in Cz for the patients, regardless of their medi-
cation pattern.
Table 3.  Mean values (standard deviations in parentheses) of the demographic and clinical variables measured 
for the patients with fibromyalgia (FM) and healthy controls (HC). Results of the t-tests comparisons and effect 
sizes (Cohen’s d). VAS: Visual Analogue Scale; SSS: Symptom Severity Score; WPI: Widespread Pain Index; 









Mean (SD) t p Cohen’s d
Age 26 50.31 (9.20) 27 48.44 (11.18) 0.66 n.s. –
Years of education 26 9.96 (4.06) 23 11.26 (4.16) − 1.11 n.s. –
VAS pain 28 6.24 (1.64) 30 3.23 (3.33) 4.42  <  0.001 1.15
VAS health status 28 6.14 (2.09) 30 3.65 (2.97) 3.70  <  0.01 0.97
VAS mood status 27 5.93 (2.40) 30 3.75 (2.97) 3.03  <  0.01 0.81
VAS non-restorative sleep 28 6.96 (2.28) 30 3.61 (3.22) 4.60  <  0.001 1.20
SSS 25 10.48 (1.16) 29 7.62 (1.95) 6.64  <  0.001 1.78
WPI 25 12.52 (4.32) 29 1.86 (1.98) 11.35  <  0.001 3.17
BDI 27 22.93 (10.78) 23 10.96 (5.60) 6.01  <  0.001 1.39
PSQI total 27 13.48 (5.06) 20 5.70 (3.80) 5.77  <  0.001 1.74
Figure 3.  Right. Auditory evoked potentials (AEPs) at electrodes Fz and Cz elicited by the tones of 70 dB 
(S1; blue line), 90 dB (S2; black line) and, 105 dB (S3; red line) in patients with fibromyalgia (FM) and healthy 
controls (HC). Left. Scalp distribution of AEP amplitudes elicited by the three stimuli. The upper part shows the 
topography of N1 (measured as the mean value from 80 to 150 ms), and the lower part shows the topography of 
P2 (measured from 150 to 300 ms).
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Table 4.  Left: Mean N1-P2 amplitude (in µV) in Fz and Cz electrodes for each tone intensity (standard 
deviation in parentheses), for the patients (FM) and healthy controls (HC). Right. Repeated measures ANOVA 
analysis significant results and effect sizes (Cohen’s d).
Stimuli
FM (n = 26) HC (n = 30) ANOVA results
N1-P2 amplitude N1-P2 amplitude
F (p) Cohen’s dFz Cz Fz Cz
S1 (70 dB) 5.41 (2.20) 5.92 (2.18) 5.96 (1.91) 6.45 (2.12) Electrode effect 34.72 (<  0.001) 1.59
S2 (90 dB) 6.39 (2.87) 7.62 (2.78) 6.75 (2.41) 8.40 (2.70) Intensity effect 20.55 (<  0.001) 1.24
S3 (105 dB) 5.37 (2.77) 7.48 (2.79) 6.08 (2.45) 8.66 (2.80) Electrode × intensity effect 18.31 (<  0.001) 1.15
Figure 4.  Auditory evoked potentials (AEPs) at electrodes Fz (up) and Cz (down) elicited by the tones of 
70 dB (S1; blue line), 90 dB (S2; black line) and, 105 dB (S3; red line) in patients with FM (without medication 
(UNMED), and with medication of the CNS (MED)).
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Discussion
It is generally assumed that patients with FM present central alterations in the processing of both nociceptive 
and non-nociceptive  stimuli58. The hypotheses of generalized hypervigilance, central sensitization, and reduced 
habituation have been proposed as possible explanatory mechanisms of the FM  syndrome10,17,18,26. However, the 
evidence is far from being conclusive. Studies analyzing brain activity when processing somatosensory stimula-
tion found evidence in favor of those pathophysiological  mechanisms13–18. Nevertheless, in the auditory modality 
the presence of augmented processing is not always observed. To provide clarity in this field, we carried out two 
studies recording auditory evoked potentials (AEPs) elicited by tones of various intensities in women diagnosed 
with FM and healthy controls, using different stimuli sequences. The peak-to-peak amplitude of the N1-P2 
complex, a reliable index of the amount of neural resources devoted to the processing of auditory  stimuli35,59, 
was evaluated in both studies. In addition, the effect of medication and the possible relationship between the 
amplitude/intensity function of the AEPs and the symptomatic picture of the patients were analyzed. Contrary 
to our hypothesis, we did not find a generalized pattern of sensory amplification in the patients, irrespective of 
the stimuli sequence used.
Since bottom-up sensory amplification of nociceptive input may be one cause of the FM  symptoms60, in 
study 1 we assessed the processing of auditory stimuli when bottom-up mechanisms were engaged. To this 
end, we used a random presentation of stimuli, where the loudest tones involuntarily capture the participants’ 
 attention32. Given the hypervigilance -generalized to all kinds of sensory information- assumed for  fibromyalgia26, 
we expected patients to have higher N1-P2 amplitudes in response to the tones, specially to the most intense 
ones. Although we found a significant interaction between Group and Intensity (interestingly, with smaller 
AEPs to the more intense tones in the patients), group differences did not reach significance in the post-hoc 
comparisons. Therefore, our results do not support the presence of increased processing of auditory stimuli in 
the patients. In addition, the data do not show evidence of alterations in the automatic assignment of attentional 
resources to the tones in the patients.
In study 2, we used a presentation in blocks of stimuli of the same intensity to study the effect of anticipatory/
preparatory attention on auditory processing. As the most intense tones were predictable, the subjects could 
anticipate their appearance and put into operation their sensory input inhibitory mechanisms to attenuate their 
impact. Given that previous studies have found deficits in sensory inhibition in FM, either using somatosensory 
noxious  stimuli2–6 or annoying high intensity auditory  stimulation19,22, we expected larger AEPs in the patients, 
specially in response to the loudest tones. Nevertheless, the findings showed similar brain responses in patients 
and controls: both groups seem to retain the integrity of their inhibition mechanisms and show a reduction in 
AEPs amplitude to the 105 dB tones. Thus, although the patients normally report hypersensitivity to  noise19,20,24, 
our results from study 2 do not support either the presence of increased processing of auditory stimuli.
This pattern of results is in line with previous studies questioning the generalizability of increased processing 
and hypervigilance to the auditory  modality14,15,23,24 but disagrees with previous reports of increased AEPs to 
auditory tones in patients with  FM19,21,26. In particular, our study could not replicate the results by Carrillo-de-
la-Peña et al.22, who also used a block presentation and found increased N1-P2 responses to the 105 dB tones in 
FM patients. Comparing that paper with the present one, we detected a fundamental difference in relation to the 
patients’ medication: they had a wash-out period of 2 weeks while here patients were not asked to discontinue 
their medication.
In animal models, it has been proposed that the intensity dependence of AEPs may be an index of serotonergic 
 function36–38. That system can be altered by medication with 5-HT effects, which is commonly used by patients 
with FM. To clarify this issue, we performed additional analyses, using only the FM group. We found that patients 
with medication affecting the CNS (mainly antidepressants, anxiolytics, analgesics, and anticonvulsants) showed 
an overall reduction in N1-P2 amplitudes. Similarly, previous literature showed a reduced slope of N1-P2 after 
antidepressant treatment in healthy  volunteers34,61,62.
Previous literature in FM found that serotonin levels are related to central sensitization and impaired descend-
ing inhibitory  pathways63. Taking into account the hypothesized relationship between the intensity dependence 
of the AEPs and serotonin  levels36–38, and the relationship between serotonin function and pain  inhibition39,40, 
we expected to find significant correlations between the N1-P2 amplitude/intensity slope and fibromyalgia 
symptoms’ severity. However, as also reported by Triñanes et al.64, we did not found a significant relation. This 
lack of correlation between AEPs slope and FM severity could be explained by the effect of medication, since 
patients with more severe symptoms likely take more medication, which in turn may reduce AEPs’ amplitude.
One of the main limitations of the present study is the lack of control of medication used by patients with 
FM. Although it would be desirable to have a wash-out period, this measure is not free from criticisms. First, it 
is questionable to ask patients discontinue treatment when pain and the other symptoms are very severe, what 
could result in a selection of the mild severity patients. In addition, a wash-out period could produce withdrawal 
adverse effects (drug dependence), also difficult to control. In any case, the medication effects observed in this 
report should be taken into account in the design and analyses of future studies. Another possible limitation 
is the lack of a subjective evaluation of the tones by the participants. Since many studies report the presence of 
subjective auditory hypersensitivity in  FM19–21, it would be interesting to include the patients’ subjective assess-
ment of intensity and unpleasantness of the presented stimuli. In order to obtain a more homogeneous sample, 
we only used women, what limits generalization of results to men. Moreover, since the age-of-onset of menopause 
modulates pain and non-pain sensitivity in women with  FM65, it would be interesting to take into account the 
early transition to menopause of the participants in future research.
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Conclusions
As a conclusion, using a large sample of participants, we could not replicate previous reports of impaired inhibi-
tory modulation of high intensity tones in patients with FM, independently of the attentional mechanism engaged 
in the performance of the task. Altough this pattern of findings may challenge the hypothesis of the hypersensitiv-
ity/hypervigilance in the auditory modality, given the observed effects of medication, we could not discard it as an 
etiopathological mechanism for fibromyalgia. Future studies on the brain activity of FM patients should take into 
account the critical role of pharmacological treatments with central effects. Altogether, these findings are relevant 
for the search of objective biomarkers and explanatory theories for fibromyalgia using event-related potentials.
Data availability
The datasets used and/or analysed during the current study are available from the corresponding author on 
reasonable request.
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